Abstract
ObjectiveThis study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.MethodsSerum MCP-1 and TGF-β1 levels in PM/DM patients complicated with ILD, patients with pulmonary infections and normal controls (n = 30, each) were detected using enzyme-linked immunosorbent assay (ELISA), and the correlation between PM/DM complicated with ILD and serum MCP-1 and TGF-β1 levels was analyzed.ResultsSerum MCP-1 and TGF-β1 levels were both higher in PM/DM patients complicated with ILD compared with patients with pulmonary infections and normal controls.ConclusionSerum MCP-1 and TGF-β1 levels increased in PM/DM patients, and were closely correlated to the complication of ILD. This finding can be used for distinguishing between pulmonary infections and ILD, providing a new diagnostic method for the early prediction of DM/PM complicated with ILD.
Highlights
Polymyositis (PM) and dermatomyositis (DM) are a group of unexplained inflammatory diseases characterized by lesions on the skeletal muscles and skins [1]
Serum MCP-1 and Transforming growth factor-β1 (TGF-β1) levels in PM/DM patients were detected by enzyme-linked immunosorbent assay (ELISA), to investigate the possible role of MCP-1 and TGF-β1 in the pathogenesis of PM/DM complicated with interstitial lung disease (ILD), and to provide a new diagnostic method for the early prediction as well as prognosis of DM/PM complicated with ILD
To further explore the roles of MCP-1 and TGF-β1 in the process of pathological changes in PM/DM complicated with ILD, the investigators analyzed the changes in serum MCP-1 and TGFβ1 levels before and after treatment
Summary
Polymyositis (PM) and dermatomyositis (DM) are a group of unexplained inflammatory diseases characterized by lesions on the skeletal muscles and skins [1]. In lung tissues of ILD patients, MCP-1 is expressed in epithelial cells, macrophages and vascular endothelial cells; MCP-1 is involved in inflammation and fibrosis response in the process of pulmonary fibrosis by recruiting and activating monocytes and lymphocytes, and is involved in the extracellular matrix deposition and changes in normal lung structure by promoting the proliferation of desmocytes, the secretion of collagen and the production of fibrosis-promoting cytokines, which all contribute to the occurrence and development of ILD [3]. Transforming growth factor-β1 (TGF-β1) can promote a number of key steps of pulmonary fibrosis, such as the apoptosis of alveolar epithelial cells, the activation and formation of fiber cells and deposition of the extracellular matrix, Wu et al Eur J Med Res (2019) 24:12 increasing the collagen secretion of desmocytes, and inducing abnormalities in the micrangium structure and reactivity, which can cause fibrosis of the skin and viscera [4]. Serum MCP-1 and TGF-β1 levels in PM/DM patients were detected by enzyme-linked immunosorbent assay (ELISA), to investigate the possible role of MCP-1 and TGF-β1 in the pathogenesis of PM/DM complicated with ILD, and to provide a new diagnostic method for the early prediction as well as prognosis of DM/PM complicated with ILD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
